← 返回

基因工程鼠伤寒沙门氏菌靶向诱导 IFNγ是抑制胰腺神经内分泌肿瘤小鼠模型肝转移的关键

英文原题:Targeted IFNγ induction by a genetically engineered Salmonella typhimurium is the key to the liver metastasis inhibition in a mouse model of pancreatic neuroendocrine tumor.

查看英文原题

Targeted IFNγ induction by a genetically engineered Salmonella typhimurium is the key to the liver metastasis inhibition in a mouse model of pancreatic neuroendocrine tumor.

PubMed 2023/10/31(内容时间) Front Med (Lausanne) Q1 · IF 3.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们证明 YB1 可能主要基于 IFNγ诱导发挥抗肿瘤作用。靶向 IFNγ治疗可替代 YB1 用于治疗 PNETs 肝转移。

研究思路结论见上方概要

肝转移是胰腺神经内分泌肿瘤(PNETs)患者的主要死亡原因之一。然而,迄今为止尚未开发出治愈性疗法。

评估了基因工程肿瘤靶向鼠伤寒沙门氏菌YB1在无功能性INR1G9肝转移模型上的抗肿瘤疗效。通过Cytometric Bead Array筛选差异炎症因子。采用抗体清除实验和肝靶向AAV2/8表达载体对差异炎症因子进行功能评估。

我们证明YB1作为单一疗法显示出显著的抗肿瘤疗效。由于YB1无法感染INR1G9细胞,其抗肿瘤作用可能是通过调节肿瘤免疫微环境实现的。给予YB1后,肝脏中两种炎症因子IFNγ和CCL2升高,但仅发现IFNγ与抗肿瘤作用相关。IFNγ的肝脏靶向表达引起巨噬细胞和NK细胞的活化,并重现了YB1对肝转移的治疗效果。

展开英文摘要原文

Liver metastasis is one of the primary causes of death for the patients with pancreatic neuroendocrine tumors (PNETs). However, no curative therapy has been developed so far.

The anti-tumor efficacy of a genetically engineered tumor-targeting Salmonella typhimurium YB1 was evaluated on a non-functional INR1G9 liver metastasis model. Differential inflammatory factors were screened by Cytometric Bead Array. Antibody depletion assay and liver-targeted AAV2/8 expression vector were used for functional evaluation of the differential inflammatory factors.

We demonstrated that YB1 showed significant anti-tumor efficacy as a monotherapy. Since YB1 cannot infect INR1G9 cells, its anti-tumor effect was possibly due to the modulation of the tumor immune microenvironment. Two inflammatory factors IFNγ and CCL2 were elevated in the liver after YB1 administration, but only IFNγ was found to be responsible for the anti-tumor effect. Liver-targeted expression of IFNγ caused the activation of macrophages and NK cells, and reproduced the therapeutic effect of YB1 on liver metastasis.

We demonstrated that YB1 may exhibit anti-tumor effect mainly based on IFNγ induction. Targeted IFNγ therapy can replace YB1 for treating liver metastasis of PNETs.

论文信息

作者
Hua Z、Wu S、Zhang Y、Wang X、Cui J、Li Y、Yang C、Zhai M
第一作者单位
Department of General Surgery, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.China
通讯作者单位
Research Center for Translational Medicine, Cancer Stem Cell Institute, East Hospital, Tongji University School of Medicine, Shanghai, China.China
期刊
Frontiers in medicine2023
原文标识
PubMed 38020179 · DOI 10.3389/fmed.2023.1284120